{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["63(10)"],"submitter":["Caporali R"],"funding":["AbbVie","Eli Lilly and Company"],"pubmed_abstract":["<h4>Objectives</h4>To evaluate the long-term efficacy of once-daily baricitinib 4 mg or 2 mg in patients with active rheumatoid arthritis who had inadequate response (IR) to MTX, csDMARDs or bDMARDs.<h4>Methods</h4>Data from three completed phase III studies-RA-BEAM (MTX-IR), RA-BUILD (csDMARD-IR) and RA-BEACON (bDMARD-IR)-and one completed long-term extension study (RA-BEYOND) were analysed up to 6.5 years [340 weeks (RA-BEAM) and 336 weeks (RA-BUILD and RA-BEACON)]. Low disease activity (LDA) [Simplified Disease Activity Index (SDAI) ≤11], clinical remission (SDAI ≤3.3) and physical function [Health Assessment Questionnaire Disability Index (HAQ-DI) ≤0.5] were the main outcomes assessed. Completer and non-responder imputation (NRI) analyses were conducted on each population.<h4>Results</"],"journal":["Rheumatology (Oxford, England)"],"pagination":["2799-2809"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11443035"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study."],"pmcid":["PMC11443035"],"pubmed_authors":["Fang Y","Mo D","Bello N","Taylor PC","Zaremba-Pechmann L","Dougados M","Aletaha D","Caporali R","Sanmarti R","Haladyj E","Takeuchi T"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study.","description":"<h4>Objectives</h4>To evaluate the long-term efficacy of once-daily baricitinib 4 mg or 2 mg in patients with active rheumatoid arthritis who had inadequate response (IR) to MTX, csDMARDs or bDMARDs.<h4>Methods</h4>Data from three completed phase III studies-RA-BEAM (MTX-IR), RA-BUILD (csDMARD-IR) and RA-BEACON (bDMARD-IR)-and one completed long-term extension study (RA-BEYOND) were analysed up to 6.5 years [340 weeks (RA-BEAM) and 336 weeks (RA-BUILD and RA-BEACON)]. Low disease activity (LDA) [Simplified Disease Activity Index (SDAI) ≤11], clinical remission (SDAI ≤3.3) and physical function [Health Assessment Questionnaire Disability Index (HAQ-DI) ≤0.5] were the main outcomes assessed. Completer and non-responder imputation (NRI) analyses were conducted on each population.<h4>Results</","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-04-21T03:28:20.515Z","creation":"2025-04-06T12:48:40.824Z"},"accession":"S-EPMC11443035","cross_references":{"pubmed":["38258434"],"doi":["10.1093/rheumatology/keae012"]}}